139 related articles for article (PubMed ID: 32667102)
1. Attitudes on pharmacogenetic testing in psychiatric patients with treatment-resistant depression.
McCarthy MJ; Chen Y; Demodena A; Fisher E; Golshan S; Suppes T; Kelsoe JR
Depress Anxiety; 2020 Sep; 37(9):842-850. PubMed ID: 32667102
[TBL] [Abstract][Full Text] [Related]
2. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression.
McCarthy MJ; Chen Y; Demodena A; Leckband SG; Fischer E; Golshan S; Suppes T; Kelsoe JR
J Psychopharmacol; 2021 Aug; 35(8):992-1002. PubMed ID: 33938307
[TBL] [Abstract][Full Text] [Related]
3. [Treatment-resistant depression and antidepressant plasma level: Proposal of a pharmacogenetic-integrative algorithm from a case report].
Bourla A; Chaneac E; Ferreri F
Encephale; 2019 Feb; 45(1):92-94. PubMed ID: 29887302
[No Abstract] [Full Text] [Related]
4. Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis.
Espadaler J; Tuson M; Lopez-Ibor JM; Lopez-Ibor F; Lopez-Ibor MI
CNS Spectr; 2017 Aug; 22(4):315-324. PubMed ID: 27098095
[TBL] [Abstract][Full Text] [Related]
5. Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.
Lee YM; Manzoor BS; Cavallari LH; Nutescu EA
Pharmacotherapy; 2018 Feb; 38(2):205-216. PubMed ID: 29286540
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic testing in primary care could bolster depression treatment: A value proposition.
Sperber NR; Roberts MC; Gonzales S; Bendz LM; Cragun D; Haga SB; Wu RR; Omeogu C; Kaufman B; Petry NJ; Ramsey LB; Uber R
Clin Transl Sci; 2024 Jun; 17(6):e13837. PubMed ID: 38898561
[TBL] [Abstract][Full Text] [Related]
7. Potential consumers' attitudes toward psychiatric genetic research and testing and factors influencing their intentions to test.
Laegsgaard MM; Kristensen AS; Mors O
Genet Test Mol Biomarkers; 2009 Feb; 13(1):57-65. PubMed ID: 19309275
[TBL] [Abstract][Full Text] [Related]
8. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.
Rosenblat JD; Lee Y; McIntyre RS
J Clin Psychiatry; 2017 Jun; 78(6):720-729. PubMed ID: 28068459
[TBL] [Abstract][Full Text] [Related]
9. Patients' Perspectives on Psychiatric Pharmacogenetic Testing.
Liko I; Lai E; Griffin RJ; Aquilante CL; Lee YM
Pharmacopsychiatry; 2020 Nov; 53(6):256-261. PubMed ID: 32583391
[TBL] [Abstract][Full Text] [Related]
10. Primary Care Providers' Interest in Using a Genetic Test to Guide Alcohol Use Disorder Treatment.
Williams EC; Young JP; Achtmeyer CE; Hendershot CS
J Subst Abuse Treat; 2016 Nov; 70():14-20. PubMed ID: 27692183
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study.
Perlis RH; Mehta R; Edwards AM; Tiwari A; Imbens GW
Depress Anxiety; 2018 Oct; 35(10):946-952. PubMed ID: 29734486
[TBL] [Abstract][Full Text] [Related]
12. Motivations and psychosocial impact of genetic testing for HNPCC.
Esplen MJ; Madlensky L; Butler K; McKinnon W; Bapat B; Wong J; Aronson M; Gallinger S
Am J Med Genet; 2001 Sep; 103(1):9-15. PubMed ID: 11562928
[TBL] [Abstract][Full Text] [Related]
13. Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved.
Gawronski BE; Cicali EJ; McDonough CW; Cottler LB; Duarte JD
Front Genet; 2022; 13():1085994. PubMed ID: 36712853
[No Abstract] [Full Text] [Related]
14. [Pharmacogenetics in future medical care -- implications for patients and physicians].
Rogausch A; Brockmöller J; Himmel W
Gesundheitswesen; 2005 Apr; 67(4):257-63. PubMed ID: 15856385
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic Testing: Why Is It So Disappointing?
Limandri BJ
J Psychosoc Nurs Ment Health Serv; 2019 Apr; 57(4):9-12. PubMed ID: 30933297
[TBL] [Abstract][Full Text] [Related]
16. Patients' and physicians' perspectives on pharmacogenetic testing.
Rogausch A; Prause D; Schallenberg A; Brockmöller J; Himmel W
Pharmacogenomics; 2006 Jan; 7(1):49-59. PubMed ID: 16354124
[TBL] [Abstract][Full Text] [Related]
17. Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care.
Thompson C; Steven P Hamilton ; Catriona Hippman
Psychiatry Res; 2015 Mar; 226(1):68-72. PubMed ID: 25618469
[TBL] [Abstract][Full Text] [Related]
18. Validity of the Maudsley Staging Method in Predicting Treatment-Resistant Depression Outcome Using the Netherlands Study of Depression and Anxiety.
van Belkum SM; Geugies H; Lysen TS; Cleare AJ; Peeters FPML; Penninx BWJH; Schoevers RA; Ruhe HG
J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29370485
[TBL] [Abstract][Full Text] [Related]
19. The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives.
Fabbri C; Corponi F; Souery D; Kasper S; Montgomery S; Zohar J; Rujescu D; Mendlewicz J; Serretti A
Int J Neuropsychopharmacol; 2019 Feb; 22(2):93-104. PubMed ID: 29688548
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.
Bousman CA; Arandjelovic K; Mancuso SG; Eyre HA; Dunlop BW
Pharmacogenomics; 2019 Jan; 20(1):37-47. PubMed ID: 30520364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
